CN|EN
About Us
Our Company Our Strengths Our Leadership
Innovative Solutions
Intelligent Clinical Operations Medical Services Regulatory Affairs Pharmacovigilance Data Science Real-World Insights Independent Assessment Center
Patient Services
TrialNet Recruitment Platform Subject Service Platform
Careers
Find Your Passion Healthy Lifestyle Growth And Development Experienced Hire
Contact Us
Contact Information Online Message
Taimei Technology
|
CN
CN EN
MENU
Our Strengths
About Us Our Strengths Our Leadership
Patient-Centered, Digital Transformation Of Clinical Trials
Refined Operation, Excellent Delivery
With years of experience and industry resources, Taimei Intelligence has continuously improved the clinical informatization management level and data value mining ability, established an international delivery team, and enhanced the professional service ability to create higher value for clients.
AI-Powered Innovation Across the Product Lifecycle
Driving Digital Transformation and Delivering Superior Outcomes
Digital Technology Improves Clinical Study Management and Operation Efficiency
Internal management
Digital operation system
  • eCooperate (CTMS)/Clinical Trial Management System
  • eArchives (eTMF)/Electronic Trial Master File management system
  • In-site and Insight Cloud (IIC)/Site think tank
  • electronic outcome assessment (eCOA)/Electronic patient-reported outcome system
  • eCollect (EDC)/Electronic data Captur system
  • eBalance (IWRS)/Randomization and Trial Supply Management
External connection
Innovative Solutions
  • iDCT/Remote intelligent clinical research platform
  • iRMS/ Randomization and Trial Supply Management
  • eTrial/Phase 1 ward system
  • eSite/Clinical research organization management system
Average CRO industry working years for core business team members
Year
  • 12 -
  • 10 -
  • 8 -
  • 6 -
  • 4 -
  • 2 -
  • 0 -
  • 6
    Medical Affairs
  • 5
    Biostastics
  • 6
    RWE
  • 4
    Data Management
  • 8
    Project Management
  • 8
    Regulatory Affairs
  • 4
    Clinical Operations
  • 3
    Pharmacovigilance
Our Project Experience
Note:The above information is updated until May 2022.
Project experience
  • Solid Tumor -
    20%
  • Hematologic malignancies -
    17%
  • Cardiovascular diseases -
    9%
  • Respiratory tract inflammation -
    9%
  • Nephrology -
    7%
  • Dermatology -
    5%
  • Ophthalmology -
    5%
  • Urinary/Bladder -
    6%
  • Other infectious diseases -
    4%
  • Immune-mediated inflammatory diseases -
    4%
  • Women's health -
    2%
  • Antiviral therapy -
    2%
  • Hematology -
    2%
  • General hormones -
    2%
  • Metabolic and cardiovascular risk -
    2%
  • Psychiatric disorders -
    2%
  • Cancer supportive care -
    2%
    • | 0
    • | 2
    • | 4
    • | 6
    • | 8
    • | 10
    • | 12
    • | 14
    • | 16
    • | 18
    • | 20
Project type
  • 0%
  • 5%
  • 10%
  • 15%
  • 20%
  • 25%
  • 30%
  • 35%
  • 40%
  • 45%
  • 50%
17%
Phase I & BE
9%
Phase II
18%
Phase III
43%
Phase IV & Postmarketing
22%
Phase IV &
Postmarketing
Sponsors
51%
49%
Domestic
Overseas
  • Headquarters
    6F, Block 24, No.1999 Yishan Road, Minhang District, Shanghai
    bd@taimei.com
Copyright©2025    Taimei Intelligence Co., Ltd.
沪ICP备 2020033173号-1    沪公网安备：31010402008670号
Contact Us
Please complete the form below to submit your request or questions.